Author: Rekha Olivia
Department of Clinical Pharmacy, Faculty of Pharmacy,
Airlangga University, Gubeng, Surabaya, East Java, Indonesia
Abstract
Angiotensin II receptor blockers (ARBs) represent a new class of antihypertensive drugs. The mechanism of action of ARB differs from angiotensin-converting (ACE) enzyme inhibitors, which also affect the renin-angiotensin system. The eight ARBs as antihypertensive approved by the FDA were candasartan, telmisartan, valsartan, losartan, irbesartan, eprosartan, olmesartan, azilsartan, while the ninth ARBs approved by the Korea Food and Drug Administration was fimasartan. ARB has a clinical profile that is very similar but it has a different pharmacokinetic profile.
